Publications IIS/FJD

  1. Scientific Publication 2021. Bachiller M, Perez-Amill L, Battram AM, Carné SC, Najjar A, Verhoeyen E, Juan M, Urbano-Ispizua A, Martin-Antonio B. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer. 2021 Aug;9(8):e002866. doi: 10.1136/jitc-2021-002866. PMID: 34433634; PMCID: PMC8388291.
  2. Scientific Publication 2021. Battram AM, Bachiller M, Lopez V, Fernández de Larrea C, Urbano-Ispizua A, Martín-Antonio B. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers (Basel). 2021 Jul 14;13(14):3534. doi: 10.3390/cancers13143534. PMID: 34298748; PMCID: PMC8304527.
  3. Scientific Publication 2021. Martín-Antonio B. Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy. Front Immunol. 2021 Mar 19;12:666703. doi: 10.3389/fimmu.2021.666703. PMID: 33815428; PMCID: PMC8017175.
  4. Scientific Publication 2020. Bachiller M, Battram AM, Perez-Amill L, Martín-Antonio B. Natural Killer Cells in Immunotherapy: Are We Nearly There? Cancers (Basel). 2020 Oct 27;12(11):3139. doi: 10.3390/cancers12113139. PMID: 33120910; PMCID: PMC7694052.
  5. Scientific Publication 2020. Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, MartÍn-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C. CAR T cells targeting options in the fight against multiple myeloma. Panminerva Med. 2021 Mar;63(1):37-45. doi: 10.23736/S0031-0808.20.04146-4. Epub 2020 Sep 21. PMID: 32955187.
  6. Scientific Publication 2020. Battram AM, Bachiller M, Martín-Antonio B. Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword. Int J Mol Sci. 2020 Jun 18;21(12):4346. doi: 10.3390/ijms21124346. PMID: 32570952; PMCID: PMC7352478.
  7. Scientific Publication 2020. Castella M, Caballero-Baños M, Ortiz-Maldonado V, González-Navarro EA, Suñé G, Antoñana-Vidósola A, Boronat A, Marzal B, Millán L, Martín-Antonio B, Cid J, Lozano M, García E, Tabera J, Trias E, Perpiña U, Canals JM, Baumann T, Benítez-Ribas D, Campo E, Yagüe J, Urbano-Ispizua Á, Rives S, Delgado J, Juan M. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Front Immunol. 2020 Mar 20;11:482. doi: 10.3389/fimmu.2020.00482. PMID: 32528460; PMCID: PMC7259426.
  8. Scientific Publication 2020. Perez-Amill L, Suñe G, Antoñana-Vildosola A, Castella M, Najjar A, Bonet J, Fernández-Fuentes N, Inogés S, López A, Bueno C, Juan M, Urbano-Ispizua Á, Martín-Antonio B. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica. 2021 Jan 1;106(1):173-184. doi: 10.3324/haematol.2019.228577. PMID: 31919085; PMCID: PMC7776337.
  9. Scientific Publication 2019. Martín-Antonio B, Suñe G, Najjar A, Perez-Amill L, Antoñana-Vildosola A, Castella M, León S, Velasco-de Andrés M, Lozano F, Lozano E, Bueno C, Estanyol JM, Muñoz-Pinedo C, Robinson SN, Urbano-Ispizua A. Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. J Immunother Cancer. 2019 Oct 16;7(1):259. doi: 10.1186/s40425-019-0739-1. PMID: 31619273; PMCID: PMC6794915.
  10. Scientific Publication 2018. Castella M, Boronat A, Martín-Ibáñez R, Rodríguez V, Suñé G, Caballero M, Marzal B, Pérez-Amill L, Martín-Antonio B, Castaño J, Bueno C, Balagué O, González-Navarro EA, Serra-Pages C, Engel P, Vilella R, Benitez-Ribas D, Ortiz-Maldonado V, Cid J, Tabera J, Canals JM, Lozano M, Baumann T, Vilarrodona A, Trias E, Campo E, Menendez P, Urbano-Ispizua Á, Yagüe J, Pérez-Galán P, Rives S, Delgado J, Juan M. Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Mol Ther Methods Clin Dev. 2018 Dec 6;12:134-144. doi: 10.1016/j.omtm.2018.11.010. PMID: 30623002; PMCID: PMC6319086.
  11. Scientific Publication 2018. Castella M, Fernández de Larrea C, Martín-Antonio B. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. Int J Mol Sci. 2018 Nov 15;19(11):3613. doi: 10.3390/ijms19113613. PMID: 30445802; PMCID: PMC6274949.
  12. Scientific Publication 2018. Perez-Amill L, Marzal B, Urbano-Ispizua A, Juan M, Martín-Antonio B. CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients. Turk J Haematol. 2018 Nov 13;35(4):217-228. doi: 10.4274/tjh.2018.0196. Epub 2018 Sep 6. PMID: 30185400; PMCID: PMC6256819.
  13. Clinical Trial. Clinical Trial phase II/III: “Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody” (NCT04309981).